We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Video Player

Who We Are

We are advancing an innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases.        more +

Video Player

Who We Are

We are advancing an innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases.        more +

Our Pipeline

We target earlier key steps in the inflammatory cascade to interrupt disease progression.

more

Latest News

Mar 18, 2025GRI Bio Participates in a Virtual Investor CEO Connect Segment
Access the CEO Connect segment here LA JOLLA, CA, March 18, 2025 (GLOBE NEWSW...
Read More
Mar 17, 2025GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ("IPF")
Interim data and topline data readouts from Phase 2a biomarker study expected i...
Read More
Mar 11, 2025GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule
LA JOLLA, CA, March 11, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (...
Read More

Sign Up!

Stay up to date by receiving our email alerts with our latest news and information.

more +

Investor Info

Nasdaq:
GRI
03/25/2025 4:03 PM
$6.70
more +

Corporate Presentation

Corporate Presentation